experiance

Artificial Intelligence is rapidly embedding itself into everyday business transactions. This includes marketing, add copy, product launches, lead generation and customer outreach.

Almost every company must begin to incorporate AI strategies or risk being out marketed or our positioned. 

In 2016, seven million people used remote monitoring and connected medical devices as part of their care. That number could jump to 50.2 million in five years. By the end of 2023 the remote patient monitoring (RPM) market is expected to earn more than $31.3 billion. This would be up from $15.8 billion in 2017, an increase of more than 97%, and growing at a 19% CAGR. More than 47% of future growth is expected to come from US markets.  

SMG works directly with software developers, device manufacturers, RCM and remote calls centers to meet the growing demand for adoption., including those seeking CCM.

We continue to see innovation in medical devices, especially with digital connectivity, miniaturization and minimally invasive technology. Wearable medical technologies, incorporating AI predictability and continuous patient monitoring is one of the fastest growing segments in healthcare.

Employers spend millions of dollars on healthcare for their employees and over 80% is spent on chronic disease; cancer and heat disease. In addition, loss in productivity, absenteeism, disability or the loss of a key employee adds to those costs.

SMG developed a diagnostic employee benefit program that identifies asymptomatic, previously undiagnostic high risk employees with early signs of heart disease and cancer. Early detection and treatment is the key to survival and lower costs. 

Stem Cells and PRP continue to show promise and clinical efficacy as patients seek alternative to surgery. SMG works with several suppliers and providers introducing the latest advancements and clinical therapies. 

Diagnostic imaging using CT and MRI, continues to expand as better technology and more medical associations/societies support emerges. In fact, CT procedures reached an all time high in 2019 with an est. 91.4M scans. 

Cash pay CT and full body scanning procedures continue to grow as more and more patients enroll in  Executive Medicine & Concierge programs. 

SMG works closely with diagnostic testing laboratories offering the latest technology and advancements in en vitro diagnostic assays. Technology advancements, for the rapid detection of bacterial infections (UTI & sepsis), antibiotic susceptibility (AST), CgX, PgX, etc. utilizing PCR and NextGen Sequencing, continues to evolve and gain greater adoption by providers. In addition, drug screening, medication compliance and blood analysis volumes as we move more into personalized medicine. 

Chronic diseases affect 6 in 10 adult Americans, of which, 43% have more than one chronic condition. The Centers for Disease Control and Prevention estimates that chronic conditions account for most deaths in the U.S. and were responsible for 90% of healthcare expenditures in 2016.

SMG clients focus on the prevention, detection and treatment of chronic conditions helpingh improve outcomes, lower risk of motality and save money. 

Antibiotic resistance has reached pandemic proportions and is a leading concern for world health agencies. Over-use and mis-use of antibiotics, as a result of empiric, prophylactic prescribing is cited as a leading cause. 

Our clients are leading the fight on early detection and diagnosis of bacterial infections with precision antibitic therapy for only those patients that need treatment.  

Infectious disease is a world health concern and a leading cause of death, hospitalization and treatment costs.  Demand for faster, more accurate and cost effective diagnostic testing has resulted in significant investments in the clinical laboratory space. 

Over-use and mis-use of Opioid pain medications for managing both chronic and acute pain has cost lives and the healthcare system billions of dollars. Both the human costs and healthcare costs have seen a growing demand for alternative pain therapies, including drugs, devices and protocols. 

SMG has served several emerging companies that have developed alternative pain therapies with the goal of reducing un-necessary opioid exposure, improving outcomes, increased patient satisfaction and reducing overall costs.  

Pharmacy operations, patient and medication mgt. and costs containment continue to force Rx's into re-evaluating their business models. Demands for lowering costs, including access to generics and alternative medicines, are being layered with needs for easier access and compliance programs.